Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Application symbols : Lly save search
Innovent's First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of China
Published: 2024-02-07 (Crawled : 09:00) - prnewswire.com
LLY | News | $745.46 -0.71% 940K
|
Health Technology
|
| O: 0.76%
H: 4.31%
C: 2.11%
SNY | News | $45.445 -1.44% 2.6M
|
Health Technology
|
| O: 1.33%
H: 0.0%
C: 0.0%
INCY | $52.59 -0.25% 880K
|
Health Technology
|
| O: -0.65%
H: 0.57%
C: -3.21%
first management drug application china
Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis
Published: 2023-12-04 (Crawled : 23:00) - prnewswire.com
LLY | News | $745.46 -0.71% 940K
|
Health Technology
|
| O: 0.08%
H: 0.0%
C: 0.0%
VNDA | News | $4.9 -6.49% 2.6M
|
Health Technology
|
| O: 2.08%
H: 1.53%
C: 0.76%
drug food treatment pharmaceuticals application
Innovent Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the New Drug Application for Parsaclisib (PI3Kδ inhibitor) for the Treatment of Relapsed or Refractory Follicular Lymphoma
Published: 2023-01-06 (Crawled : 05:00) - prnewswire.com
SNYNF | News | $92.7 1.4K
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: -2.69%
LLY | News | $745.46 -0.71% 940K
|
Health Technology
|
| O: 0.3%
H: 1.86%
C: 0.82%
SNY | News | $45.445 -1.44% 2.6M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
INCY | $52.59 -0.25% 880K
|
Health Technology
|
| O: 1.05%
H: 0.2%
C: -0.16%
treatment designation drug medical application granted review china
UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Supports Expedited Review of Marketing Authorization Application for Sabizabulin Treatment in Hospitalized COVID-19 Patients
Published: 2022-07-25 (Crawled : 12:00) - globenewswire.com
LLY | News | $745.46 -0.71% 940K
|
Health Technology
|
| O: 0.0%
H: 1.07%
C: 0.85%
VERU | $1.38 18.97% 4.9M
|
Health Technology
|
| O: 3.41%
H: 0.07%
C: -8.65%
covid-19 treatment sabizabulin application review authorization
Innovent and Ascentage Pharma Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML
Published: 2022-07-19 (Crawled : 01:00) - biospace.com/
LLY | News | $745.46 -0.71% 940K
|
Health Technology
|
| O: 0.72%
H: 1.02%
C: 0.65%
INCY | $52.59 -0.25% 880K
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
treatment designation pharma drug application granted review china
Innovent and Ascentage Pharma Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML
Published: 2022-07-20 (Crawled : 01:00) - prnewswire.com
LLY | News | $745.46 -0.71% 940K
|
Health Technology
|
| O: 0.27%
H: 0.22%
C: -1.55%
INCY | $52.59 -0.25% 880K
|
Health Technology
|
| O: 2.32%
H: 1.21%
C: 0.99%
treatment designation pharma drug application granted review china
Ascentage Pharma and Innovent Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML
Published: 2022-07-19 (Crawled : 17:00) - prnewswire.com
LLY | News | $745.46 -0.71% 940K
|
Health Technology
|
| O: 0.72%
H: 1.02%
C: 0.65%
INCY | $52.59 -0.25% 880K
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
treatment designation pharma drug application granted review china
Triastek announces research collaboration with Lilly to explore the application of 3D printing technology in oral delivery of drugs
Published: 2022-07-14 (Crawled : 02:00) - prnewswire.com
LLY | News | $745.46 -0.71% 940K
|
Health Technology
|
| O: -1.53%
H: 3.22%
C: 2.94%
research collaboration application technology
Innovent Announces the NMPA Acceptance of the New Drug Application for Tafolecimab Injection (anti-PCSK-9 antibody)
Published: 2022-06-14 (Crawled : 01:00) - prnewswire.com
LLY | News | $745.46 -0.71% 940K
|
Health Technology
|
| O: -0.49%
H: 0.98%
C: 0.56%
INCY | $52.59 -0.25% 880K
|
Health Technology
|
| O: -2.09%
H: 0.41%
C: -1.96%
drug application injection
Veru Submits Emergency Use Authorization (EUA) Application to U.S. FDA for Sabizabulin, its Novel, Oral Antiviral and Anti-Inflammatory Drug Candidate for Hospitalized COVID-19 Patients at High Risk for ARDS
Published: 2022-06-07 (Crawled : 11:00) - globenewswire.com
LLY | News | $745.46 -0.71% 940K
|
Health Technology
|
| O: -3.62%
H: 0.0%
C: 0.0%
VERU | $1.38 18.97% 4.9M
|
Health Technology
|
| O: -2.57%
H: 17.21%
C: 13.21%
covid-19 fda risk drug antiviral application authorization emergency use authorization
Innovent and IASO Bio Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Published: 2022-06-06 (Crawled : 01:00) - prnewswire.com
SANA | $7.755 -6.11% 1.2M
|
|
| O: 5.56%
H: 2.46%
C: -13.16%
LLY | News | $745.46 -0.71% 940K
|
Health Technology
|
| O: 3.83%
H: 0.0%
C: 0.0%
INCY | $52.59 -0.25% 880K
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
treatment drug application
IASO Bio and Innovent Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Published: 2022-06-02 (Crawled : 17:00) - biospace.com/
SANA | $7.755 -6.11% 1.2M
|
|
| O: -6.1%
H: 9.2%
C: 8.6%
LLY | News | $745.46 -0.71% 940K
|
Health Technology
|
| O: -0.9%
H: 0.0%
C: 0.0%
INCY | $52.59 -0.25% 880K
|
Health Technology
|
| O: -0.4%
H: 0.25%
C: -0.07%
treatment drug application
Innovent Announces NMPA of China Acceptance of a Supplemental New Drug Application for TYVYT®
Published: 2021-12-24 (Crawled : 14:00) - biospace.com/
INCY | $52.59 -0.25% 880K
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $745.46 -0.71% 940K
|
Health Technology
| Email alert
Add to watchlist
tyvyt new drug application drug china
Innovent Announces NMPA of China Acceptance of a Supplemental New Drug Application for TYVYT® (Sintilimab Injection plus Bevacizumab Biosimilar Injection and Chemotherapy in Patients with EGFR-mutated Non-squamous Non-small Cell Lung Cancer who Progressed after EGFR-TKI Therapy
Published: 2021-12-24 (Crawled : 11:00) - prnewswire.com
INCY | $52.59 -0.25% 880K
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $745.46 -0.71% 940K
|
Health Technology
| Email alert
Add to watchlist
tyvyt new drug application drug cel lung cancer china therapy injection cancer biosimilar
US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction
Published: 2021-11-11 (Crawled : 19:00) - prnewswire.com
LLY | News | $745.46 -0.71% 940K
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
new drug fda heart application drug fda acceptance
Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with Chemotherapy as First-Line Treatment for Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Published: 2021-11-04 (Crawled : 09:00) - prnewswire.com
LLY | News | $745.46 -0.71% 940K
|
Health Technology
|
| O: 3.16%
H: 0.0%
C: 0.0%
INCY | $52.59 -0.25% 880K
|
Health Technology
|
| O: 2.41%
H: 0.0%
C: 0.0%
new drug treatment application therapy drug
Dicerna Announces FDA Clearance of Investigational New Drug (IND) Application for DCR-AUD for the Treatment of Alcohol Use Disorder
Published: 2021-07-29 (Crawled : 21:00) - biospace.com/
NVO | News | $122.675 -1.49% 2.1M
|
Health Technology
|
| O: 0.49%
H: 0.26%
C: -0.62%
LLY | News | $745.46 -0.71% 940K
|
Health Technology
|
| O: 0.4%
H: 0.3%
C: -0.88%
ALNY | $144.675 -0.44% 130K
|
Health Technology
|
| O: -0.01%
H: 1.3%
C: -0.14%
new drug alcohol use disorder fda clearance treatment fda drug application clearance
Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for LY3819469
Published: 2021-05-27 (Crawled : 13:00) - biospace.com/
NVO | News | $122.675 -1.49% 2.1M
|
Health Technology
|
| O: -1.58%
H: 0.7%
C: -0.32%
LLY | News | $745.46 -0.71% 940K
|
Health Technology
|
| O: -0.17%
H: 0.36%
C: -0.72%
ALNY | $144.675 -0.44% 130K
|
Health Technology
|
| O: 0.57%
H: 1.91%
C: 0.46%
new drug fda fda acceptance drug application
Iterative Scopes Announces Partnership with Eli Lilly and Company to Advance AI Applications for Inflammatory Bowel Disease (IBD) Clinical Trials
Published: 2021-02-11 (Crawled : 19:00) - biospace.com/
LLY | News | $745.46 -0.71% 940K
|
Health Technology
|
| O: -0.74%
H: 0.65%
C: -0.14%
disease partnership trial application
Gainers vs Losers
| 69% | 31% |
Top 10 Gainers
AGBA | $1.05 162.5% 100M
|
Finance
ISPC | $0.4621 116.95% 15M
|
Professional, Scientific, and T...
INVO | $1.515 99.34% 4.3M
|
Health Technology
BPTH | $5.62 73.46% 75M
|
Health Technology
TIRX | $0.8231 69.78% 54M
|
XPON | $2.63 36.27% 8.4M
|
PRTG | $0.299 35.17% 120K
|
Mining, Quarrying, and Oil and ...
VTNR S | $1.26 28.68% 9.1M
|
Industrial Services
SWVL | $9.64 27.35% 200K
|
n/a
DFLI A | $0.7726 25.52% 4.3M
|
Your saved searches
Save your searches and get alerts when important news are released.